5 Pharmaceutical preparations for the prevention of diseases of the nervous system; pharmaceutical preparations for treating metabolic disorders; chemical preparations for pharmaceutical purposes for the treatment of diseases of the nervous system, metabolic disorders, malignant tumors, for activating cellular function, for cardiovascular and cerebrovascular diseases, for the treatment of Parkinson's disease, for the prevention of diseases of the respiratory system, for gastro-intestinal disorders, for the treatment of infectious diseases, for movement disorders, for oncologic diseases, for immune system diseases, for skeletal muscular diseases, for hormone disorders, for skin diseases, for ophthalmologic disease, for gynecological diseases, for hematological diseases and for pediatric diseases; pharmaceutical agents affecting metabolism; pharmaceutical preparations for treating malignant tumors; pharmaceutical preparations for activating cellular function; medicines for the treatment of cardiovascular and cerebrovascular diseases; pharmaceutical preparations for the treatment of parkinson's disease; pharmaceutical preparations for the prevention of diseases of the respiratory system; pharmaceutical preparations for the treatment of rare diseases being hereditary movement disorders such as Huntington disease, Tourette disease, tardive dyskinesia, hereditary muscular dystrophies, hereditary metabolic disorders, hereditary neurological diseases, amyloidosis, rare neurodegenerative diseases, myotonic dystrophy, spinal muscular atrophy, idiopathic pulmonary fibrosis, multiple sclerosis, neurofibromatosis, Acute Flaccid Myelitis, Devic's syndrome, rare cancers, neuropathic pain, ELA and diabetes; pharmaceuticals, for use in the field of treatment of hereditary diseases being Huntington's Disease, Phenylketonuria, Tay Sachs, Duchenne Muscular Dystrophy, Dystrophinopathies, GM2 gangliosidoses, Niemann Pick Disease, hereditary amyloidosis, hereditary Parkinson's Disease, adrenoleukodystrophy, Dravet syndrome, Batten disease, Fragile X syndrome, Friedrich Ataxia, Lennox Gastaut, Gaucher disease, cystic fibrosis, acute myeloid leukemia, sickle cell disease; pharmaceutical preparations for the treatment of gastro-intestinal disorders; pharmaceutical products for the treatment of infectious diseases; pharmaceuticals, for use in treatment of movement disorders; pharmaceutical preparations for use in oncology; pharmaceuticals for the treatment of immune system disease; pharmaceuticals, for use in the treatment of skeletal muscular diseases; pharmaceuticals, for use in the treatment of hormone disorders; pharmaceuticals, for use in the treatment of skin diseases; pharmaceutical preparations for use in ophthalmology; pharmaceuticals, for use in the treatment of gynaecological diseases; pharmaceuticals, for use in the treatment of haematological diseases; pharmaceuticals, for use in the treatment of paediatric diseases; reagents for use in medical genetic testing; clinical medical reagents; drug delivery agents consisting of compounds that modulate delivery of a wide range of pharmaceuticals; pharmaceutical preparations, namely, drug detoxifying agents; central nervous system stimulants; respiratory stimulants; cardiovascular drugs used in treating congestive heart failure (CHF); preparations for detecting genetic predispositions for medical purposes; cells for medical use; tumor suppressing agents; pharmaceutical preparations for treatment of tumors, namely, tumor antigens; biopharmaceuticals for the treatment of cancer